markets.businessinsider.com
Eli Lilly’s Omvoh for Crohn’s disease approved by FDA
A new FDA approval means an additional biologic treatment option for adults with moderate to severe Crohn's disease. This may affect treatment choices and insurance coverage discussions for people with IBD.
Adult patients with moderately to severely active Crohn's disease, patients on or considering biologic therapies, gastroenterologists, and IBD researchers.
What To Know
Omvoh (Eli Lilly) has received FDA approval for moderately to severely active Crohn's disease in adults; the article notes this follows an earlier approval in ulcerative colitis and references Phase 3 VIVID-1 results and ongoing VIVID-2 study. The approval is presented as a regulatory and market update rather than a clinical guideline.
What To Know Omvoh is now approved in the U.S. for moderately to severely active Crohn's disease in adults and previously received approval for ulcerative colitis. The article cites Phase 3 VIVID-1 data as the basis for approval and mentions an ongoing longer-term study (VIVID-2).
If you are taking or considering biologic treatments, this expands the number of approved options for adult IBD patients; talk with your gastroenterology team about whether Omvoh may be relevant to your care and how it compares with treatments you are already using.
The piece is a market/regulatory brief aimed at investors and does not provide clinical details such as dosing, safety profile, or comparative effectiveness. For treatment decisions or detailed safety information, consult prescribing information and your clinician.
This is a regulatory/market report summarizing FDA approval based on Phase 3 trial results; it does not include clinical details, safety data, or guidance on how Omvoh compares with other therapies. Patients should consult clinicians and official prescribing information for clinical implications.
